Statin use substantially reduces the risk of hepatocellular carcinoma and should be considered as a standard of care in patients at high risk for the disease, according to a Cleveland Clinic meta-analysis.
The Threat of Hepatitis B In Those Receiving Immune Suppression Drugs
Study presented at AASLD 2018 looks at physician compliance rate with hepatitis B screening prior to administering immunosuppressive drugs and the incidence of hepatitis B reactivation.
Thoughts on Thoughtful Vaccination
Brian Mandell, MD, PhD, Editor in Chief of Cleveland Clinic Journal of Medicine and staff in the Department of Rheumatic and Immunologic Diseases, reflects on the intricacies of vaccination in the immunosuppressed.
Deadly but Preventable: HBV Reactivation After Immunosuppressive Treatment
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy